Abstract
Background: This was follow up of twenty five female patients of operable breast cancer in a prospective study in a tertiary care centre over a period of one year from 1st September,2006 to 31st August,2007 regarding response to neoadjuvant chemotherapy and conversion of modified radical mastectomy to breast conservation surgery.
Aim: To observe the events during years of follow up and to study whether breast conservation surgery in carefully selected responders could prove to be a better alternative.
Material and Methods: The study was conducted in fine needle aspiration cytology proven operable breast cancer patients with ductal histology. Inclusion criteria were female patients with complete haemogram, liver function tests, renal function tests within normal limits, Karnofsky score more than fifty and age below 70 years. Exclusion criteria were patients with pregnancy or previous history of thoracic irradiation.
Results: 16 of 25 patients were offered breast conservation surgery after neoadjuvant chemotherapy according to selection criteria and kept on follow up after treatment completion. Two patients developed ipsilateral breast recurrence at four and six years of follow up respectively.
Conclusion: Breast conservation surgery seems to be a safe and better alternative in carefully selected responders.
Keywords: Neoadjuvant chemotherapy ,Breast conservation surgery, Modified radical mastectomy
Abbreviation: BCS; Breast conservation surgery, MRM; Modified radical mastectomy, IBTR; Ipsilateral breast tumour recurrence.
References
1. Available at www.ICMR.nic.in/ncrp/cancer reg.pdf.
2. Bonadonna G , Valagussa P , Brambilla C , Ferrari L , Moliterni A, Terenziani M et al.Primary chemotherapy in Operable Breast Cancer , Eight Year Experience at the Milan Cancer Institute . J ClinOncol. 1998 Jan ; 16 (1): 93-100 .
3. Jacquillat C , Weil M , Baillet F, Borel C, Auclerc G , Maublanc de M.A.et al . Results of neoadjuvant chemotherapy and radiation therapy in breast conserving treatment of 250 patients with all stages of infiltrative breast cancer.Cancer ,1990 ; 66 : 119-129 .
4. Bonadonna G , Veronesi U , Brambilla C ,Ferrari L , Luini A , Greco M et al . Primary chemotherapy to avoid mastectomy in tumours with diameters of 3 cm or more . J Natl CancerInst .1990 Oct 3; 82(19) : 1539-1545 .
5. Smith IE , Jones AL , O Brien MER , McKinna J. A. , Sacks N , Baum M et al. Primary medical chemotherapy for operable breast cancer. Eur J Cancer. 1993 ; 29A : 1796-1799 .
6. Anderson ED , Forrest AP , Hawkins RA ,Anderson TJ ,Leonard RC , Chetty U et al.Primary Systemic Therapy for Operable Breast Cancer . Br J Cancer . 1991 Apr ;63 (4), 561-566 .
7. BougheyJC ,Pientinger F , MerieBernstam F et al . Impact of preoperative versus postoperative chemotherapy on the extent and number of surgical procedures in patients treated in randomised clinical trials for breast cancer . Ann Surg .2006 ; 244(3) : 464-470 .
8. Buchholz TA , Hunt KK , Whitman GJ , Sahin AA , Hortobagyi GN . Neoadjuvant chemotherapy for breast carcinoma . Multidisciplinary considerations of bene-fits and risks .Cancer .2003 ; 98(6) : 1150-1160.
9. Wolmark N, Wang J , Mamounas E et al . Preoperative chemotherapy in patients with operable breast cancer : nine year results from National Surgical Adjuvant Breast and Bowel Project B-18 . Natl Cancer InstMonogi .2001 : 3096-102 .
10. Fisher B , Brown A , Manoumas E et al . Effect of preoperative chemotherapy on local regional disease in women with operable breast cancer : Findings from National Surgical Adjuvant Breast and Bowel Project B-18 . J ClinOncol .1997 ; 15(7) : 2483-2493 .
11. RouzierR,Extra Marc Jean,Carlton M, Falcau M , Soloman A., Forquet A et al. Primary chemotherapy for operable breast cancer: Incidence and Prognostic Significance of Ipsilateral Breast Tumour Recurrence After Breast Conserving Surgery . J ClinOncol . 2001 Sept 15; 19 : 3828-3835 .
12. Kuerer HM , Singletary SE , Buzdar AU, Ames FC , Valero V , Buchholz TA et al Surgical Conservation Planning after neoadjuvant chemotherapy for stage II and Operable Stage III Breast Cancer. Am J Surg. 2001 Dec ; 18(6) : 601-8 .
13. Mauriac L ,Macgragon G , Avril A et al . Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm : A unicentre randomised trial with a124 month median follow up. Institut Bergonie BourdeauxGroupeSein (IBBGS) . Ann Oncol .1999; 19(1): 47-52.
14. BeriwalS , Swartz GF , Komarnicky L , Jorge A, Young G . Breast Conserving Therapy after neoadjuvantchemotherapy : Long term results . The Breast Journal .2006 ; 12(2) : 159-164.
15. TeshomeM, Hunt K K . Neoadjuvant Therapy in the Treatment of Breast Cancer Surg Oncol Clin N Am 2014 .
16. Egan RL. Mammography, Report on 2000 studies. Surgery .1963; 53 (3: 291-302
17. Wolfe JN . Mammography , Report on its use in women with breasts abnormal and normal on physical examination . Pro Lesummario in inter lingua . 1964 ; 83 : 2144-2154 .
18. Diguisto C , Ouldamer L , Arbion F , Vilde A , Body G. MRI evaluation of residual breast cancer after neoadjuvant chemotherapy: Influence of Patient , Tumour and Chemotherapy characteristics on the correlation with pathological response. Anticancer Research .2015 ; 35 : 581-586 .
19. Kaufman M, Von Minckwitz G , Mamounas EP et al . Recommendations from an international consensus conference on the current status and future of neoadjuvant systemic therapy in primary breast cancer . Ann SurgOncol . 2012 ; 19(5) : 1508-1516.
20. Buchholz TA ,Mittendorf EA , Hunt KK . Surgical considerations after neoadjuva-ntchemotherapy; Breast Conservation Therapy. J Natl Cancer InstMonogi (2015) 2015(51) : 11-14.
DOI: https://dx.doi.org/10.18535/jmscr/v5i5.116
